Galderma's Nemluvio Shows Sustained Three-Year Benefits In Atopic Dermatitis

WASHINGTON (dpa-AFX) - Galderma (GALD) reported new three-year data from the ARCADIA long-term extension study showing that Nemluvio (nemolizumab) was associated with sustained improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-sever…